MX2018001298A - Agente inductor de inmunidad. - Google Patents
Agente inductor de inmunidad.Info
- Publication number
- MX2018001298A MX2018001298A MX2018001298A MX2018001298A MX2018001298A MX 2018001298 A MX2018001298 A MX 2018001298A MX 2018001298 A MX2018001298 A MX 2018001298A MX 2018001298 A MX2018001298 A MX 2018001298A MX 2018001298 A MX2018001298 A MX 2018001298A
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- agent
- amino acid
- immunity
- treat
- Prior art date
Links
- 230000036039 immunity Effects 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 238000007792 addition Methods 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000037430 deletion Effects 0.000 abstract 1
- 238000012217 deletion Methods 0.000 abstract 1
- 239000000411 inducer Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Developmental Biology & Embryology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un objetivo de la presente invención es descubrir un nuevo péptido útil como un ingrediente activo en un agente para tratar o prevenir el cáncer, y para proporcionar el uso del polipéptido como un inductor de inmunidad. El agente inductor de inmunidad que contiene como un ingrediente activo: (a) un polipéptido que consiste de cualquiera de las secuencias de aminoácidos representadas por la SEQ ID Nos.: 35 a 67; o (b) un polipéptido que comprende una a varias eliminaciones, sustituciones y/o adiciones de aminoácidos en la secuencia de aminoácidos del polipéptido (a); es útil como un agente para tratar o prevenir el cáncer, etc.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015158539 | 2015-08-10 | ||
| PCT/JP2016/073077 WO2017026389A1 (ja) | 2015-08-10 | 2016-08-05 | 免疫誘導剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018001298A true MX2018001298A (es) | 2018-05-17 |
| MX392412B MX392412B (es) | 2025-03-24 |
Family
ID=57984435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018001298A MX392412B (es) | 2015-08-10 | 2016-08-05 | Polipéptidos que tienen actividad inductora de inmunidad. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11510971B2 (es) |
| EP (1) | EP3335725B1 (es) |
| JP (1) | JP7181676B2 (es) |
| KR (1) | KR102679914B1 (es) |
| CN (1) | CN107847573B (es) |
| AU (1) | AU2016306408B2 (es) |
| BR (1) | BR112018001542A2 (es) |
| DK (1) | DK3335725T5 (es) |
| ES (1) | ES2977955T3 (es) |
| FI (1) | FI3335725T3 (es) |
| HU (1) | HUE066530T2 (es) |
| MX (1) | MX392412B (es) |
| PL (1) | PL3335725T3 (es) |
| PT (1) | PT3335725T (es) |
| RU (1) | RU2758112C2 (es) |
| WO (1) | WO2017026389A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI3335725T3 (fi) * | 2015-08-10 | 2024-04-23 | Toray Industries | Pds5a-epitooppeja immuuniteetin indusoijina |
| JP7054418B2 (ja) | 2017-11-08 | 2022-04-13 | ビオンテック ユーエス インコーポレイテッド | Ｔ細胞を製造する組成物及び方法 |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| CN113527440B (zh) * | 2021-08-10 | 2022-12-23 | 昆明医科大学 | 一种具有提高免疫力和抗肿瘤以及延长寿命的多肽及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997009065A1 (fr) | 1995-09-07 | 1997-03-13 | Japan Tobacco Inc. | Remede contre maladies auto-immunes |
| WO2002081641A2 (en) * | 2001-04-06 | 2002-10-17 | Georgetown University | Gene scc-112 and diagnostic and therapeutic uses thereof |
| US7842467B1 (en) * | 2005-05-12 | 2010-11-30 | Celera Corporation | Breast disease targets and uses thereof |
| ES2529193T3 (es) | 2007-07-19 | 2015-02-17 | Health Research, Inc. | Péptidos de survivina como vacunas contra el cáncer |
| WO2009054710A1 (es) | 2007-10-23 | 2009-04-30 | Villegas Lopez Saul | Dispositivo lijador de interiores y/o exteriores cilindricos |
| PL2213301T3 (pl) | 2007-10-25 | 2018-05-30 | Toray Industries, Inc. | Induktor odpowiedzi immunologicznej |
| TWI543767B (zh) | 2008-08-19 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| DK2474315T3 (en) | 2009-09-03 | 2018-03-12 | Toray Industries | IMMUNITY INDUCER |
| ES2595161T3 (es) * | 2011-05-19 | 2016-12-28 | Toray Industries, Inc. | Agente inmunoinductor |
| WO2012157736A1 (ja) * | 2011-05-19 | 2012-11-22 | 東レ株式会社 | 免疫誘導剤 |
| FI3335725T3 (fi) * | 2015-08-10 | 2024-04-23 | Toray Industries | Pds5a-epitooppeja immuuniteetin indusoijina |
| WO2017184590A1 (en) * | 2016-04-18 | 2017-10-26 | The Broad Institute Inc. | Improved hla epitope prediction |
-
2016
- 2016-08-05 FI FIEP16835086.6T patent/FI3335725T3/fi active
- 2016-08-05 CN CN201680043484.5A patent/CN107847573B/zh active Active
- 2016-08-05 MX MX2018001298A patent/MX392412B/es unknown
- 2016-08-05 AU AU2016306408A patent/AU2016306408B2/en active Active
- 2016-08-05 BR BR112018001542-3A patent/BR112018001542A2/pt active Search and Examination
- 2016-08-05 PT PT168350866T patent/PT3335725T/pt unknown
- 2016-08-05 DK DK16835086.6T patent/DK3335725T5/da active
- 2016-08-05 KR KR1020187006155A patent/KR102679914B1/ko active Active
- 2016-08-05 US US15/743,869 patent/US11510971B2/en active Active
- 2016-08-05 EP EP16835086.6A patent/EP3335725B1/en active Active
- 2016-08-05 PL PL16835086.6T patent/PL3335725T3/pl unknown
- 2016-08-05 WO PCT/JP2016/073077 patent/WO2017026389A1/ja not_active Ceased
- 2016-08-05 JP JP2016555386A patent/JP7181676B2/ja active Active
- 2016-08-05 RU RU2018107330A patent/RU2758112C2/ru active
- 2016-08-05 ES ES16835086T patent/ES2977955T3/es active Active
- 2016-08-05 HU HUE16835086A patent/HUE066530T2/hu unknown
-
2022
- 2022-10-24 US US17/972,055 patent/US20230190899A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3335725A1 (en) | 2018-06-20 |
| DK3335725T3 (da) | 2024-04-02 |
| CA2993427A1 (en) | 2017-02-16 |
| BR112018001542A2 (pt) | 2018-11-06 |
| EP3335725A4 (en) | 2019-03-27 |
| RU2018107330A (ru) | 2019-09-12 |
| MX392412B (es) | 2025-03-24 |
| AU2016306408A1 (en) | 2018-02-22 |
| PL3335725T3 (pl) | 2024-07-22 |
| WO2017026389A1 (ja) | 2017-02-16 |
| US20180200356A1 (en) | 2018-07-19 |
| US20230190899A1 (en) | 2023-06-22 |
| EP3335725B1 (en) | 2024-02-28 |
| DK3335725T5 (da) | 2024-10-07 |
| JPWO2017026389A1 (ja) | 2018-05-24 |
| CN107847573A (zh) | 2018-03-27 |
| KR102679914B1 (ko) | 2024-07-01 |
| PT3335725T (pt) | 2024-05-08 |
| ES2977955T3 (es) | 2024-09-03 |
| US11510971B2 (en) | 2022-11-29 |
| CN107847573B (zh) | 2021-12-31 |
| HUE066530T2 (hu) | 2024-08-28 |
| KR20180037999A (ko) | 2018-04-13 |
| JP7181676B2 (ja) | 2022-12-01 |
| AU2016306408B2 (en) | 2021-02-11 |
| RU2018107330A3 (es) | 2020-01-31 |
| RU2758112C2 (ru) | 2021-10-26 |
| RU2021127767A (ru) | 2021-11-23 |
| FI3335725T3 (fi) | 2024-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002825A1 (es) | Vacuna contra vrs | |
| SV2018005614A (es) | Inhibidores peptidicos del receptor de interleucina 23 y uso para tratar enfermedades inflamatorias | |
| MX2018005315A (es) | Composiciones y metodos para el tratamiento del cancer. | |
| CL2017002097A1 (es) | Sulfonilureas y compuestos relacionados y uso de estos | |
| CO2017010894A2 (es) | Cuerpo mixto novedoso de compuesto de hierro y óxido de grafeno | |
| CL2016002027A1 (es) | Ciclopropilamina como inhibidor de la lsd1 | |
| MX2021007679A (es) | Anticuerpos humanos para hemaglutinina de influenza. | |
| CL2016002971A1 (es) | Combinación. | |
| MX383887B (es) | Composiciones farmacéuticas y uso de las mismas para la prevención y el tratamiento de cardiomiopatía asociada a la ataxia de friedreich. | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| CL2017001718A1 (es) | Derivados de glucagón con estabilidad mejorada | |
| MX390503B (es) | Compuesto de pirimidina fusionada o sal del mismo. | |
| CL2017001883A1 (es) | Compuestos antisenescentes y usos de los mismos | |
| CL2016002072A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| CL2016001405A1 (es) | A peptide mixture | |
| MX2019012452A (es) | Meganucleasas diseñadas especificas para secuencias de reconocimiento en el gen pcsk9. | |
| CL2020001901A1 (es) | Vacunas contra virus de la gripe y usos de las mismas. | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| CR20160316A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| MX375738B (es) | Niacinamida para inducir generacion de peptidos antimicrobianos. | |
| AR120721A2 (es) | Péptidos y composiciones para el tratamiento de daño articular | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| CU20210061A7 (es) | Composición vacunal que comprende el dominio alfa 3 de mica/b para el tratamiento del cáncer | |
| MX2018001298A (es) | Agente inductor de inmunidad. | |
| BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório |